Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support and is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolyte replacement and maintains osmotic pressure.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Parenteral rehydration,Correction of fluid and electrolyte imbalances,Provision of caloric support in patients unable to take oral nutrition
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion. Adult dose is typically 100-200 m L/hour, adjusted based on fluid and electrolyte needs, serum glucose, and clinical status.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose has an effective half-life of approximately 1.5-2 hours for equilibration with total body water; however, the terminal elimination half-life is not applicable as it is rapidly metabolized. Sodium has a elimination half-life of about 24-48 hours depending on renal function.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, producing ATP. Sodium chloride is not metabolized; it distributes in extracellular fluid and is excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
The dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of unchanged dextrose. Sodium and chloride are excreted renally, with >90% of an administered sodium load eliminated via kidneys within 24-48 hours in patients with normal renal function.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: not bound to plasma proteins. Sodium and chloride: not protein bound.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose distributes in total body water, approximately 0.55 L/kg (range 0.4-0.6 L/kg). Sodium distributes in extracellular fluid, approximately 0.2 L/kg.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% bioavailability.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
In patients with impaired renal function, dose and rate must be individualized based on fluid and electrolyte balance, renal function, and serum glucose. For GFR < 30 m L/min, reduce infusion rate and monitor closely for hypervolemia and electrolyte disturbances.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustments based on Child-Pugh classification. Use with caution in patients with hepatic impairment due to risk of fluid overload and hyperglycemia; monitor serum glucose and electrolytes.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based dosing: 5-10 m L/kg/hour as maintenance fluid, adjust based on age, weight, clinical condition, and serum glucose. For neonates and children, consider body surface area and avoid excessive glucose load.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients: Use lower initial infusion rates and titrate slowly due to decreased renal function and higher risk of fluid overload, hyperglycemia, and electrolyte abnormalities. Monitor serum glucose, renal function, and volume status closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia in diabetic patients or those with glucose intolerance,Risk of fluid overload in patients with heart failure, renal impairment, or pulmonary edema,Electrolyte imbalances (e.g., hypernatremia, hyponatremia) with administration,Use with caution in patients with increased intracranial pressure (dextrose may exacerbate),Avoid in patients with known allergy to corn or corn products (dextrose derived from corn)
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia (severe, uncontrolled),Hypersensitivity to any component,Intracranial hemorrhage (if dextrose-containing solutions may be harmful),Severe renal impairment (oliguria, anuria) without appropriate monitoring
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, patients on fluid or sodium restriction should be monitored. Diabetic patients should monitor blood glucose levels and adjust diet accordingly.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No known teratogenic risk. Dextrose and sodium chloride are normal physiological constituents. No evidence of fetal harm from IV administration at standard doses. Correct electrolyte and glucose abnormalities to prevent fetal acidosis or hyperglycemia.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose and sodium chloride are normal components of breast milk. No significant excretion; M/P ratio not applicable. Considered compatible with breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustment required. Use standard dosing based on clinical status. Monitor for gestational diabetes or preeclampsia; adjust infusion rate accordingly.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This solution provides 50g dextrose and 34 m Eq sodium per liter. It is isotonic with serum; used for maintenance hydration and mild sodium depletion. Monitor serum glucose in diabetic patients. Avoid in patients with hypernatremia or severe renal impairment. Incompatible with certain drugs; check compatibility before IV co-administration.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution is used to provide fluids and sugar to your body.,Tell your doctor if you have diabetes, high blood pressure, or kidney problems.,Report any signs of allergic reaction like rash, itching, or trouble breathing.,Inform your healthcare provider if you are pregnant or breastfeeding.,Do not use if the solution is cloudy, discolored, or contains particles.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support and is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolyte replacement and maintains osmotic pressure.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Intravenous infusion. Adult dose is typically 100-200 m L/hour, adjusted based on fluid and electrolyte needs, serum glucose, and clinical status.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are normal physiological constituents. No evidence of fetal harm from IV administration at standard doses. Correct electroly. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.